Travere Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Travere Therapeutics (TVTX).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

13Buy

2Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$50Upside to Avg. PT-11.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$75→$89
Sep 22, 2026	Wedbush	Laura Chico	Maintained	Outperform	$76
Sep 22, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$67
Aug 10, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$68→$78
Aug 6, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$62→$70
Aug 6, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$61→$75
Aug 5, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$60→$75
Aug 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$70→$85
Aug 5, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$60→$68
Aug 5, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$65→$75
Jul 30, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$56→$62
Jun 25, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$56→$65
Jun 22, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$55→$61
Jun 18, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$52→$60
Jun 15, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$62→$70
Jun 12, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$50→$65
Jun 3, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$59→$62
Jun 3, 2026	Wedbush	Laura Chico	Maintained	Outperform	$55
Jun 2, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$57→$67
May 6, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$40→$50

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.

Benzinga Newsdesk

Travere Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Travere Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

People Also Watch

People Also Watch

Travere Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Travere Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PROWedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PROHC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

PROEvercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

PROCanaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

PROWedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75